PF-Atlas › Clinical Trials › NCT05531786

Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Pacritinib · Phase 1

Registry ID

NCT05531786

Phase

Phase 1

Status

Recruiting

Drug / intervention

Pacritinib

Sponsor

National Cancer Institute (NCI)

Start

2023-03-06

About this trial

Pacritinib is evaluated in NCT05531786, a Phase 1 idiopathic pulmonary fibrosis study sponsored by National Cancer Institute (NCI). Current status: Recruiting.

View NCT05531786 on ClinicalTrials.gov →

Explore related

All Pacritinib trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT05531786 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.